AZ moves closer to Lynparza filing in breast cancer

AZ have announced that they are closer to Lynparza (olaparib) being licensed for the treatment of breast cancer. Lynparza provided a statistically-significant improvement in progression-free survival compared to chemotherapy. This is the first positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer.